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Abstract
Background: Serum osteoprotegerin (OPG) is elevated in patients with chronic kidney disease (CKD) and increases with
decreasing renal function. However, there are limited data regarding the association between OPG and renal function in the
general population. The aim of the present study was to explore the relation between serumOPG and renal function in subjects
recruited from the general population.
Methods: We conducted a cross-sectional study with 6689 participants recruited from the general population in Tromsø,
Norway. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology
Collaboration equations. OPG was modelled both as a continuous and categorical variable. General linear models and linear
regressionwith adjustment for possible confounders were used to study the association between OPG and eGFR. Analyseswere
stratified by the median age, as serum OPG and age displayed a significant interaction on eGFR.
Results: In participants ≤62.2 years with normal renal function (eGFR ≥90 mL/min/1.73 m2) eGFR increased by 0.35 mL/min/
1.73 m2 (95% CI 0.13–0.56) per 1 standard deviation (SD) increase in serum OPG after multiple adjustment. In participants older
than themedianagewith impaired renal function (eGFR<90 mL/min/1.73 m2), eGFRdecreasedby 1.54 (95%CI−2.06 to−1.01) per
1 SD increase in serum OPG.
Conclusions: OPGwas associatedwith an increased eGFR in younger subjects with normal renal function andwith a decreased
eGFR in older subjects with reduced renal function. Our findings imply that the association between OPG and eGFR varies with
age and renal function.
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Introduction
The glycoprotein osteoprotegerin (OPG) and its cytokine network
has been proposed to represent a link between the skeletal and
cardiovascular systems [1]. OPG is a member of the tumour ne-
crosis factor receptor superfamily [2] and functions as a decoy re-
ceptor for receptor activator of nuclear factor κB ligand (RANKL)
[3]. RANKL is necessary for the differentiation and activation of
osteoclasts [3]. Serum OPG is a marker of cardiovascular disease
[4–9] and is increased in patients with diabetes mellitus [10].
Development of osteoporosis and subintimal vascular calcifi-
cation are both prominent features in OPG double knockout mice
[11]. Patients with chronic kidney disease (CKD) have a high
prevalence of cardiovascular mineralization and reduced bone
mineral density [12]. Even at a predialytic stage, more than half
of CKD patients have some form of cardiovascular calcification
and reduced bone formation [13].
Progression of impaired renal function is inversely related to
serum OPG in patients with CKD [14]. Plasma OPG has also
been found to be associated with coronary artery calcification
in patients undergoing haemodialysis [15] and a predictor of
all-cause mortality and cardiovascular mortality after adjust-
ment for cardiovascular risk factors [16]. Furthermore, serum
OPG was associated with cardiovascular events, cardiac mortal-
ity and all-cause mortality in kidney transplant patients [17, 18]
and predicted graft failure in one of the studies [18]. Moreover,
elevated OPG at baseline was associated with a more rapid and
greater magnitude of reduced glomerular filtration rate (GFR) in
elderly women from the general population [19].
There is a paucity of data regarding the relation between OPG
and renal function across age groups in the general population. In
the present large, cross-sectional, population-based study with a
wide age span, we aimed to investigate the relationship between
serum OPG and renal function in subjects with normal and
impaired renal function.
Materials and methods
Study population
Participants were recruited from the fourth survey of the Tromsø
Study (conducted in 1994–95), a single-centre prospective, popu-
lation-based study, with repeated health surveys of inhabitants
in Tromsø, Norway. The fourth survey consisted of two visits,
where all inhabitants 55–74 years of age and 5–10% of random
samples in the other 5-year age groups (25–54 and 75–85 years)
were eligible for the second visit. Seventy-eight per cent (n = 6887)
of the eligible subjects attended. Furthermore, subjects were ex-
cluded due to a lack of consent to contribute to research (n = 57).
Measurement of OPG and/or creatinine was lacking in 141
subjects. Thus 6689 participants were included in the present
study. Informed written consent was obtained from all partici-
pants and the study was approved by the regional committee
for research ethics.
Medical history, blood collection and measurements
Information about the study participants was obtained from self-
administrated questionnaires, anthropometric measurements,
and measurements of non-fasting blood samples. In brief,
blood samples were collected from an antecubital vein and
serum prepared by centrifugation after 1 h respite at room tem-
perature. OPG concentrations were analysed in freshly thawed
serum aliquots stored at −70°C for 12 years by an enzyme-linked
immunosorbent assay (R&D Systems, Abingdon, UK) withmouse
anti-human OPG as capture antibody. Biotinylated goat anti-
human OPG and streptavidin horseradish peroxidase were used
for detection. The OPG assay was performed according to the
manufacturer’s instructions. The intra- and interassay coeffi-
cients of variation (CVs) in our laboratory were 6.5 and 9.3%,
respectively. Between-assay variations in OPG were adjusted for
by use of an internal standard. All samples were analysed in
duplicate and the mean value was used in this report. Serum
lipids [total and high-density lipoprotein (HDL) cholesterol
and triglycerides], haemoglobin A1c (HbA1c), high-sensitivity
C-reactive protein (hs-CRP) and creatinine were assessed as
previously described [20].
Assessment of renal function
Plasma creatininewas analysed byamodified Jaffe reaction, but a
subsamplewas reanalysedwith an enzymaticmethod and recal-
culated creatinine values were used for the estimation of GFR
(eGFRcrea) [21]. eGFR was calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equations [22].
CKD was categorized based on the National Kidney Foundation
guidelines using eGFRcrea: eGFR≥90 mL/min/1.73 m2 for normal
kidney function, eGFR between 60 and 89 mL/min/1.73 m2 for
mildly impaired kidney function and eGFR between 15 and
59 mL/min/1.73 m2 for Stage 3–4 CKD [23].
Statistical methods
The frequency distribution for all variables was checked by inspec-
tion of the distribution curves. Continuous variables are presented
asmeanswith 95% confidence intervals (CIs) or standard deviation
(SD). Categorical data are presented as numbers or percentages. A
general linear model (GLM) or logistic regression models were
used for sexandageadjustment forcontinuousandbinarydepend-
ant variables. The χ2 test for linear trendwas applied for categorical
variables. OPG was modelled both as a continuous and categorical
variable (tertiles in the analyses). GLM was used to test for linear
trends across categories of OPG and linear regression was used to
analyse OPG as a continuous variable. Crude analyses, adjustment
for age and gender and further adjustments were carried out for
variables shown to be associatedwith OPG (cardiovascular disease,
smoking, body mass index, calcium, hypertension, HDL choles-
terol, hs-CRP, self-reported diabetes mellitus, non-fasting glucose
level≥11.1mmol/L or HbA1c >6.1%).Model assumptionswere care-
fully checked andassessed by residual analysis. Testsof interaction
between gender and OPG and between age and OPG were per-
formed by including cross-product terms between the variables.
There were significant interactions between age and OPG on
eGFR. Therefore, we stratified the participants in two groups
according to age (above and below median age). Subjects with
incomplete data for the assessed covariates were excluded from
the multivariable models (<1%). The statistical analyses were
performed using SPSS for Windows, version 23.0 (IBM, Armonk,
NY, USA). Two-sided P-values <0.05 were considered statistically
significant. Figures were made in GraphPad Prism 7.00 (GraphPad
Software, La Jolla, CA, USA).
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Results
The characteristics of the study participants are summarized in
Table 1. The mean age was 61.0 years. eGFR was ≥90 mL/min/
1.73 m2 in 63.1%, between 60 and 89.9 in 34.8% and <60 in 2.1%
of the participants (n = 6689). The serum concentration of OPG in-
creased significantly across categories of eGFR. Serum OPG in-
creased linearly across categories of renal function from
3.11 ± 0.94 ng/mL in subjects with normal renal function (eGFR
≥90 mL/min/1.73 m2) to 3.71 ± 1.30 in subjects with mildly im-
paired renal function (eGFR 60–89) and to 4.50 ± 1.54 in subjects
with Stage 3–4 CKD (eGFR 15–59). Subjects with normal renal
function were, on average, about 10 years younger than subjects
with impaired renal function. The Pearson correlation coefficient
between OPG and age was 0.49.
Age- and gender-adjusted characteristics of participants
stratified by tertiles of OPG are shown in Table 2. No significant
trend in eGFR was found across categories of OPG (P = 0.497).
Age, blood pressure, total cholesterol, HDL cholesterol, HbA1c,
CRP, creatinine, fibrinogen, calcium, percentage of smokers and
persons with self-reported cardiovascular disease, hypertension
or diabetesmellitus increased significantly across tertiles of OPG,
whereas the percentage of men, BMI and triglycerides decreased.
Differences in eGFR across tertiles of OPG in the total study popu-
lation in the crude analysis and after adjustment for age, sex,
smoking, systolic blood pressure, BMI, plasma calcium, CRP,
HDL cholesterol, hypertension, CVD (ischaemic stroke and/or
myocardial infarction before baseline) and diabetes mellitus are
shown in Figure 1. A significant interaction between OPG and age
was found in the multivariable model (P = 0.0003) but not be-
tween OPG and gender.
Table 3 shows the relation betweenOPG and eGFR stratified by
age. In participants ≤62.2 years of age (median), no significant
association was found after multivariable adjustment. In con-
trast, in participants older than the median age, eGFR decreased
across tertiles of OPG (P < 0.0001) and per 1 SD higher level of OPG
(P < 0.0001) (Table 3).
The relation between tertiles of OPG and eGFR stratified by
renal function is shown in Figure 2. In subjects with normal
renal function (eGFR≥90mL/min/1.73m2), eGFR increased signifi-
cantly (P-value trend <0.0001) across tertiles of OPG (panel A). The
increase in eGFR per 1 SD increase in OPG was 0.43 mL/min/
1.73 m2 (95% CI 0.26–0.60; P < 0.0001). In participants with im-
paired renal function (eGFR <90mL/min/1.73m2), eGFR decreased
significantly (P-value trend <0.0001) across tertiles of OPG (panel
B) and decreased by −1.07 mL/min/1.73 m2 (95% CI −1.53 to
−0.60; P < 0.0001) per 1 SD increase in OPG. Tables 4 and 5 show
the relation between OPG and eGFR in participants ≤62.2 years
of age (median) and >62.2 years, respectively. Significant positive
associations betweenOPGandeGFR in subjectswith normal renal
function who were younger than the median age were found
(Table 4). However, no significant association was present in
younger subjects with impaired renal function (Table 4). No sig-
nificant association was found between OPG and eGFR in partici-
pants older than the median age with normal renal function
(Table 5). However, significant negative associations were present
in subjects with impaired renal function in the oldest age group.
Discussion
In the present large population-based cross-sectional study in-
cluding participants 25–85 years of age, a positive association be-
tweenOPG and eGFRwas found inparticipantswith normal renal
function (eGFR ≥90.0 mL/min/1.73 m2) and an inverse associ-
ation was found in participants with reduced renal function
Table 1. Characteristics of participants overall and across categories of eGFR
eGFRcrea (mL/min/1.73 m2)
Overall ≥90 60–89 15–59 P-value (trend)
Participants, n (%) 6689 4219 (63.1) 2328 (34.8) 142 (2.1)
Age (years) 61.0 (10.1) 57.7 (10.2) 66.6 (6.9) 68.3 (5.7) <0.0001
Male sex, n (%) 3298 (49.3) 2161 (51.2) 1070 (46.0) 67 (47.2) 0.0001
Osteoprotegerin (ng/mL) 3.34 (1.15) 3.11 (0.94) 3.71 (1.30) 4.50 (1.54) <0.0001
eGFR (mL/min/1.73 m2) 92.3 (13.4) 100.0 (7.8) 80.8 (7.4) 50.7 (9.5) <0.0001
Creatinine (µmol/L) 67.6 (16.1) 61.6 (10.0) 75.3 (11.4) 117.8 (50.5) <0.0001
BMI (kg/m2) 26.0 (4.0) 25.8 (3.9) 26.3 (3.9) 27.2 (4.1) <0.0001
Systolic BP (mmHg) 145 (23) 142 (21) 150 (23) 156 (26) <0.0001
Diastolic BP (mmHg) 83 (13) 82 (13) 85 (13) 88 (15) <0.0001
Total cholesterol (mmol/L) 6.72 (1.25) 6.64 (1.27) 6.84 (1.20) 7.05 (1.32) <0.0001
HDL cholesterol (mmol/L) 1.52 (0.42) 1.53 (0.42) 1.52 (0.42) 1.43 (0.40) 0.013
Triglycerides (mmol/L) 1.63 (0.93) 1.59 (0.96) 1.69 (0.85) 1.98 (0.95) <0.0001
Fibrinogen (g/L) 3.39 (0.85) 3.34 (0.85) 3.46 (0.83) 3.88 (0.96) <0.0001
CRP (mg/L) 2.70 (6.51) 2.56 (6.33) 2.85 (6.73) 4.35 (7.44) 0.040
Plasma calcium (mmol/L) 2.38 (0.11) 2.37 (0.11) 2.39 (0.11) 2.40 (0.13) <0.0001
PTH (pmol/L) 4.68 (2.13) 4.49 (1.90) 4.91 (2.27) 6.54 (3.95) <0.0001
HbA1c (%) 5.48 (0.68) 5.45 (0.70) 5.50 (0.60) 5.73 (0.93) <0.0001
Current smoking, n (%) 2117 (31.7) 1539 (36.5) 549 (23.6) 29 (20.4) <0.0001
CVD, n (%)a 477 (7.1) 213 (5.0) 234 (10.1) 30 (21.1) <0.0001
Hypertension, n (%)b 3972 (59.4) 2256 (53.6) 1603 (68.9) 113 (79.6) <0.0001
Diabetes mellitus, n (%)c 386 (5.8) 222 (5.3) 146 (6.3) 18 (12.7) 0.02
Continuous variables are reported as mean (SD).
BMI, body mass index; BP, blood pressure; PTH, parathyroid hormone; CVD, cardiovascular disease.
aSelf-reported ischaemic stroke and/or myocardial infarction before baseline.
bAntihypertensive medication and/or systolic blood pressure ≥140 mmHg and/or diastolic BP ≥90 mmHg.
cSelf-reported use of glucose-lowering drugs, non-fasting glucose level ≥11.1 mmol/L or HbA1c ≥6.5%.
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(eGFR <90.0 mL/min/1.73 m2). In age-stratified analyses, a posi-
tive association between OPG and eGFR was found in younger
subjects (≤62.2 years) with normal renal function, whereas an in-
verse association was present in older subjects (>62.2 years) with
reduced renal function. The modest changes in eGFR across ter-
tiles of OPG are probably of questionable clinical relevance. How-
ever, our study shows that the relation between OPG and eGFR
varies between age groups and stages of renal function.
An inverse relation between serum OPG and eGFR has previ-
ously been reported in elderly women. Subjects with serum
OPG greater than the median serum concentration had 5%
lower eGFR compared with those with lower serum OPG [19].
Furthermore, elevated OPG at baseline predicted a more rapid
and greater decline in eGFRduring follow-up [19]. Corresponding-
ly, we found an inverse association between OPG and eGFR in
participants older than the median age. In contrast, we found a
positive association between OPG and eGFR in subjects with nor-
mal renal function, accounting for the majority of the study
population.
Vascular calcification is a prominent feature in renal disease
and the term ‘chronic kidney disease–mineral bone disorder’ re-
flects the interplay between various organ systems [12]. More
than half of patients with predialytic renal failure have vascular
calcification and reduced bone formation [13]. An association be-
tween serum OPG and rapid progression of vascular calcification
has been reported in dialysis patients [24]. In contrast, animal
studies indicate that OPG acts as an inhibitor of both atheroscler-
otic plaque growth and vascular calcification. Both osteoporosis
and subintimal vascular calcification occurred in OPG−/− mice
[11] and increased vascular calcification and plaque size ap-
peared in double knockoutmice (Apo E−/− and OPG−/−) compared
with Apo E−/− OPG+/+ mice [25]. Serum OPG increased within a
few weeks in ldlr−/− mice fed a diet promoting atherosclerosis
[26]. Administration of recombinant OPG did not influence ath-
erosclerotic plaque size, but reduced vascular calcification [26].
Consistent with findings in animal studies, we have reported
lower serum OPG in subjects with echogenic carotid plaques
compared with subjects with echolucent plaques and controls
[27]. Moreover, an inverse association between OPG and increas-
ing plaque echogenicity has also been reported in subjects with
prior cardiovascular disease [28].
It has been hypothesized that the positive association be-
tween serumOPG and future risk of cardiovascular diseases, car-
diovascular mortality and all-cause mortality might be a
Table 2. Characteristics of participants across tertiles of OPG, adjusted for age and sex (n = 6689)
T1, 0.46–2.80 ng/mL T2, 2.80–3.59 ng/mL T3, 3.59–25.81 ng/mL P-value (trend)
Number 2229 2230 2230
eGFR (mL/min/1.73 m2) 92.1 (91.6, 92.5) 92.9 (92.4, 93.3) 91.9 (91.4, 92.3) 0.497
Age (years)a 54.0 (53.7, 54.4) 61.9 (61.5, 62.2) 67.1 (66.7, 67.5) <0.0001
Male (%)b 58.2 48.1 41.9 <0.0001
Current smoker (%) 26.7 32.4 35.4 <0.0001
Body mass index (kg/m2) 26.4 (26.2, 26.6) 26.0 (25.9, 26.2) 25.6 (25.5, 25.8) <0.0001
Systolic BP (mmHg) 142 (141, 143) 144 (143, 145) 149 (148, 150) <0.0001
Diastolic BP (mmHg) 82 (82, 83) 83 (83, 84) 84 (84, 85) <0.0001
Total cholesterol (mmol/L) 6.64 (6.59, 6.70) 6.80 (6.75, 6.85) 6.72 (6.67, 6.77) 0.088
HDL cholesterol (mmol/L) 1.48 (1.46, 1.50) 1.54 (1.52, 1.55) 1.56 (1.54, 1.57) <0.0001
Triglycerides (mmol/L) 1.68 (1.64, 1.72) 1.62 (1.58, 1.66) 1.60 (1.55, 1.64) 0.012
HbA1c (%) 5.41 (5.38, 5.44) 5.45 (5.42, 5.48) 5.57 (5.54, 5.60) <0.0001
C-reactive protein (mg/L) 2.24 (1.94, 2.54) 2.54 (2.27, 2.81) 3.34 (3.04, 3.63) <0.0001
Fibrinogen (g/L) 3.24 (3.21, 3.28) 3.38 (3.35, 3.42) 3.55 (3.51, 3.59) <0.0001
Creatinine (µmol/L) 67.5 (66.9, 68.2) 66.7 (66.1, 67.3) 68.5 (67.9, 69.2) 0.027
Plasma calcium (mmol/L) 2.38 (2.37, 2.38) 2.38 (2.38, 2.38) 2.38 (2.38, 2.39) 0.021
PTH (pmol/L) 4.69 (4.59, 4.78) 4.60 (4.52, 4.69) 4.76 (4.66, 4.85) 0.323
CVD (%)c 4.9 4.6 6.2 0.041
Hypertension (%)d 55.3 57.2 65.9 <0.0001
Diabetes mellitus (%)e 4.1 4.6 7.4 <0.0001
Continuous variables are reported as means (95% CI) and categorical data as percentages.
BP, blood pressure; PTH, parathyroid hormone; CVD, cardiovascular disease.
aAdjusted for sex.
bAdjusted for age.
cSelf-reported ischaemic stroke and/or myocardial infarction before baseline.
dAntihypertensive medication and/or systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg.
eSelf-reported, use of glucose-lowering drugs, non-fasting glucose level ≥11.1 mmol/L or greater, or HbA1C ≥6.5%.
Fig. 1. Estimated GFR with 95% CI across tertiles of OPG in the total population
(n = 6689). Unadjusted P-value for trend <0.0001. Multivariable adjusted P-value
for trend 0.084.
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Table 3. Estimated GFR (mL/min/1.73 m2) across tertiles of OPG
Unadjusted Adjusted for age and sex Multivariable adjusted
Age ≤62.2 years n = 3345 n = 3345 n = 3301
OPG n
T1: 1115 101.6 (100.9–102.3) 98.1 (97.5–98.7) 98.2 (97.6–98.7)
T2: 1115 97.7 (97.0–98.3) 98.6 (98.0–99.1) 98.7 (98.1–99.2)
T3: 1115 96.6 (95.9–97.3) 99.2 (98.6–99.8) 99.0 (98.4–99.6)
P-value (trend) <0.0001 0.009 0.056
SD OPG 0.90 −1.89 (−2.29 to −1.49) −0.01 (−0.34–0.33) −0.07 (−0.42–0.28)
P-value <0.0001 0.972 0.708
Age >62.2 years n = 3344 n = 3344 n = 3284
OPG n
T1: 1114 88.0 (87.3–88.7) 86.6 (86.0–87.3) 86.8 (86.2–87.5)
T2: 1115 86.7 (86.0–87.4) 86.6 (85.9–87.2) 86.5 (85.8–87.1)
T3: 1115 83.0 (82.3–83.7) 84.5 (83.8–85.2) 84.3 (83.6–84.9)
P-value (trend) <0.0001 <0.0001 <0.0001
SD OPG 1.15 −2.40 (−2.79 to −2.01) −1.31 (−1.72 to −0.91) −1.43 (−1.84 to −1.02)
P-value <0.0001 <0.0001 <0.0001
Values are mean (95% CI).
Multivariablemodel adjusted for age, sex, smoking, systolic blood pressure, BMI, plasmacalcium, CRP, HDL cholesterol, hypertension, self-reportedCVD (ischaemic stroke
and/ormyocardial infarction before baseline) and diabetesmellitus (self-reported use of glucose-lowering drugs, non-fasting glucose level ≥11.1 mmol/l or HbA1c ≥6.5%).
Fig. 2. EstimatedGFRwith 95%CI aftermultivariable adjustment across tertiles of OPG. (A) Participantswith eGFR≥90 mL/min/1.73 m2 (n = 4147), P-value for trend <0.0001.
(B) Participants with eGFR <90 mL/min/1.73 m2 (n = 2438), P-value for trend <0.0001.
Table 4. Estimated GFR in participants ≤62.2 years of age stratified by renal function across tertiles of OPG and per 1 SD increase in serum OPG
Unadjusted Adjusted for age and sex Multivariable adjusted
eGFR ≥90 mL/min/1.73 m2 n = 2728 n = 2728 n = 2688
T1: 909 105.4 (104.9–105.9) 102.3 (101.9–102.6) 102.3 (102.0–102.7)
T2: 910 101.9 (101.4–102.4) 102.7 (102.4–103.1) 102.7 (102.4–103.1)
T3: 909 100.8 (100.3–101.4) 103.1 (102.8–103.5) 103.0 (102.6–103.4)
P-value (trend) <0.0001 0.002 0.013
SD OPG 0.79 −1.60 (−1.89 to −1.30) 0.45 (0.23–0.65) 0.35 (0.13–0.56)
P-value <0.0001 <0.0001 0.002
eGFR <90 mL/min/1.73 m2 n = 617 n = 617 n = 613
T1: 205 82.1 (80.9–83.2) 81.6 (80.4–82.8) 81.4 (80.1–82.6)
T2: 206 80.4 (79.2–81.6) 80.4 (79.3–81.6) 80.4 (79.3–81.6)
T3: 206 79.5 (78.3–80.7) 79.9 (78.7–81.1) 80.1 (78.8–81.3)
P-value (trend) 0.003 0.062 0.158
SD OPG 1.26 −0.80 (−1.48 to −0.11) −0.79 (−1.47 to −0.11) −0.27 (−1.20–0.66)
P-value 0.024 0.022 0.569
Values are mean (95% CI).
Multivariablemodel adjusted for age, sex, smoking, systolic blood pressure, BMI, plasmacalcium, CRP, HDL cholesterol, hypertension, self-reportedCVD (ischaemic stroke
and/or myocardial infarction before baseline) and diabetes mellitus (self-reported non-fasting glucose level ≥11.1 mmol/L or HbA1c ≥6.5%).
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response to rather than a cause of atherosclerosis or vascular
calcification in an attempt to regulate those processes [1, 10,
27]. Recently we found an age-dependent association between
serum OPG and carotid intima media thickness, where subjects
<45 years of age had a 50% lower risk of being in the uppermost
quartile of carotid intima media thickness per 1 SD increase in
serum OPG [29]. Our findings, of varying strength and direction
of the relation between serum OPG across age groups and cat-
egories of renal function, are intriguing and difficult to explain,
but may nurture the hypothesis that increased serum OPG
observed in renal failure is secondary to ageing and disease.
However, the results of a cross-sectional epidemiological study
cannot be used to distinguish between these or other potential
explanations, such as a counterregulatory mechanism.
Although epidemiological studiesmay provide valuable infor-
mation, targeted interventional studies are needed. Denosumab,
a monoclonal antibody to RANKL (decoy receptor for OPG), is
used for the treatment of osteoporosis. It remains elusive
whether long-term treatment with denosumab has effects on
the renal and cardiovascular system.
Possible explanations for increased serum concentration of
OPG with ageing, and in subjects with atherosclerosis and renal
failure, may include decreased clearance of OPG or increased
inflammatory activity. Clearance studies in rats showed that
125I-labelled OPG was rapidly and predominantly distributed to
the sinusoids of the liver after intravenous injection [30]. Thus,
if this result is transferable to humans, impaired renal function
seems a less probable explanation for the increase in serum
OPG. Inflammatorymediators are known to promote the produc-
tion of OPG [31]. As ageing, renal failure and cardiovascular dis-
ease are conditions associated with increased inflammatory
activity, it is likely that inflammatory responses may partly
explain increased serum OPG in these conditions.
The main strengths of our study are the large number of par-
ticipants from a general population, with a wide age span and
both genders represented. Possible confounding factors have
been judiciously recorded and included in themultivariable stat-
istical model, however, confounding by unmeasured factors can-
not be ruled out. Limitations also include potential sources of
misclassification. Renal function estimated by the CKD-EPI equa-
tion is not as accurate as direct measurement from iothalamate
or creatinine clearance using a 24-h urine collection. However,
direct measurement of GFR is not feasible in a large epidemio-
logical study. Furthermore, estimation of renal function was
based on only one measurement of serum creatinine and may
be subject to intra-individual variation. Serum samples were
kept frozen for 12 years at −70°C without any freezing–thawing
cycles before measurement of OPG. However, others have re-
ported long-term stability of OPG measurements in serum sam-
ples stored at −70°C [9].
Conclusions
Results from our large population-based cross-sectional study
showed that the relation between OPG and eGFR varies with
age and renal function. An inverse association was found in sub-
jects older than the median age with impaired renal function,
whereas a positive association was found in younger subjects
with normal renal function. The clinical significance of these
findings remains to be determined in future studies.
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